Shares of Stemline Therapeutics Inc (NASDAQ:STML) traded up 5.1% on Friday . The stock traded as high as $10.39 and last traded at $10.32, 547,906 shares traded hands during trading. A decline of 11% from the average session volume of 615,361 shares. The stock had previously closed at $9.81.
A number of research analysts recently issued reports on STML shares. Alliance Global Partners assumed coverage on Stemline Therapeutics in a report on Monday, November 25th. They set a “buy” rating and a $21.00 price objective for the company. Zacks Investment Research cut Stemline Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Cowen reaffirmed a “buy” rating on shares of Stemline Therapeutics in a research report on Wednesday, September 18th. BidaskClub raised shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Stemline Therapeutics in a report on Monday, November 11th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $22.57.
The firm’s 50-day simple moving average is $10.04 and its 200 day simple moving average is $12.30.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Metropolitan Life Insurance Co NY boosted its position in Stemline Therapeutics by 56.7% during the first quarter. Metropolitan Life Insurance Co NY now owns 13,358 shares of the biopharmaceutical company’s stock valued at $171,000 after purchasing an additional 4,835 shares during the last quarter. Steward Partners Investment Advisory LLC acquired a new position in shares of Stemline Therapeutics during the 2nd quarter worth approximately $67,000. SG Americas Securities LLC bought a new stake in shares of Stemline Therapeutics during the 2nd quarter worth approximately $104,000. Candriam Luxembourg S.C.A. bought a new stake in shares of Stemline Therapeutics during the 2nd quarter worth approximately $1,220,000. Finally, C WorldWide Group Holding A S boosted its holdings in shares of Stemline Therapeutics by 139.6% in the 2nd quarter. C WorldWide Group Holding A S now owns 858,082 shares of the biopharmaceutical company’s stock valued at $13,146,000 after buying an additional 500,000 shares during the last quarter. Institutional investors and hedge funds own 83.07% of the company’s stock.
Stemline Therapeutics Company Profile (NASDAQ:STML)
Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.
Featured Article: What is a growth and income fund?
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.